Breast Cancer
Conditions
Keywords
Protein turnover, Skeletal muscle deconditoning, Breast cancer, Chemotherapy, Muscle biopsy
Brief summary
Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe off-target side effects such as skeletal muscle deconditioning. To date, three different studies investigated skeletal muscle decontioning in breast cancer patients, through long term protocols including all chemotherapy cycle treatment, and highlighted both structural alterations and impaired cellular processes. However, no study is currently availbale on the acute effect of one single chemotherapy administration in breast cancer patients skeletal muscle tissue. Our study is therefore dedicated to the investigation of the acute effect of the first dose administration of both Epuribicin/cyclophosphamide and Paclitaxel chemotherapies on skeletal muscle of breast cancer patients.
Detailed description
Chemotherapy treatments such as epirubicin-cyclophosphamid or paclitaxel lead to severe off-target side effects such as skeletal muscle deconditioning. Resulting from a global perturbation of the muscle homeostasis, skeletal muscle is characterized by both structural and functional alterations that will translate into a decrease in muscle mass and/or force as well as an increase in muscle fatigability. These maladaptations result in a reduced quality of life and an increased treatment-related toxicity, ultimately leading to an increased mortality risk.To date, three different studies investigated skeletal muscle decontioning in breast cancer patients, through long term protocols including all chemotherapy cycle treatment, and highlighted both structural alterations and impaired cellular processes. However, no study is currently availbale on the acute effect of one single chemotherapy administration in breast cancer patients skeletal muscle tissue.Our study is therefore dedicated to the investigation of the acute effect of the first dose administration of both Epuribicin/cyclophosphamide and Paclitaxel chemotherapies on skeletal muscle of breast cancer patients. Our study will particularly explore cellular mechanisms of muscle decontioning, such as protein turnover, mitochondrial homeostasis and fatty infiltrations.
Interventions
DRUGEpirubicin-cyclophosphamide
1 cycle of Epirubicin-cyclophosphamide
DRUGPaclitaxel
1 cycle of Paclitaxel
Sponsors
Université de Strasbourg - Unité de Recherche 3072 - Mitochondries, Stress oxydant, Protection musculaire
Institut de cancérologie Strasbourg Europe
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Breast cancer (stade I to III) * Patient recieving the first administration of epirubicin-cyclophosphamide (group 1) or paclitaxel (group 2) for early breast cancer treatment
Exclusion criteria
* History of cancer * Known chronic pathology * Pacemaker * Contraindication to the evaluation of the physical condition * Contraindication to the local anesthesia for the muscle micro-biopsy * Breastfeeding or pregnant woman
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Investigate the acute effect of chemotherapy administration on protein turnover cellular processes through vastus lateralis biopsies of breast cancer patients | Before and 4 days after the chemotherapy | Change From Baseline in Western Blots measurements of protein expression levels |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the quality of life | Before and 4 days after the chemotherapy | Change From Baseline in FACT-G auto-questionnaire measurement |
| Investigate the acute effect of chemotherapy administration on structural alterations | Before and 4 days after the chemotherapy | Change From Baseline in Cross-Sectional Area (CSA) measurements |
| Investigate the acute effect of chemotherapy administration on inflammation | Before and 4 days after the chemotherapy | Change From Baseline in Western Blots measurments of protein expression levels |
| Investigate the acute effect of chemotherapy administration on mitochondrial homeostasis | Before and 4 days after the chemotherapy | Change From Baseline in Western Blot measurement of protein expression levels |
| Investigate the acute effect of chemotherapy administration on fatty infiltrations | Before and 4 days after the chemotherapy | Change From Baseline in Western Blot measurement of protein expression levels |
| Investigate the acute effect of chemotherapy administration on satellite cells | Before and 4 days after the chemotherapy | Change From Baseline in Western Blot measurement of protein expression levels |
| .Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the skeletal muscle mass | Before and 4 days after the chemotherapy | Change From Baseline in quantity of muscle mass measured by bioelectrical impedance analysis |
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle force | Before and 4 days after the chemotherapy | Change From Baseline in the maximal isometric strength of the knee with force transducer |
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle thickness | Before and 4 days after the chemotherapy | Change From Baseline in ultrasonography measurement |
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle fibers angle of pennation | Before and 4 days after the chemotherapy | Change From Baseline in ultrasonography measurement |
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the muscle fibers fascicle length | Before and 4 days after the chemotherapy | Change From Baseline in ultrasonography measurement |
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the echogenecity | Before and 4 days after the chemotherapy | Change From Baseline in ultrasonography measurement |
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the appetite loss | Before and 4 days after the chemotherapy | Change From Baseline in FAACT auto-questionnaire measurement |
| Comparison of the acute effect of Epirubicin-Cyclophosphamide versus Paclitaxel on the physical activity level | Before and 4 days after the chemotherapy | Change From Baseline in GPAQ auto-questionnaire measurement |
Countries
France
Outcome results
None listed